Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation

References

• Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011 Jan;140(1):124–131.
   PubMed Web of Science ®Google Scholar
• Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011 May;34(5):1139–1144.
   PubMed Web of Science ®Google Scholar
• Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004 Dec;40(6):1387–1395.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Valenti L, Bugianesi E, Pajvani U, et al. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int. 2016 Jun 8;36(11):1563–1579.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002 Jun;35(6):1485–1493.
   PubMed Web of Science ®Google Scholar
• Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009 Dec 15;115(24):5651–5661.
   PubMed Web of Science ®Google Scholar
• Murphy SK, Yang H, Moylan CA, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(5):1076–1087.
   PubMed Web of Science ®Google Scholar
• Ahrens M, Ammerpohl O, von Schönfels W, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab. 2013;18(2):296–302.
   PubMed Web of Science ®Google Scholar
• Zeybel M, Hardy T, Robinson S, et al. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics. 2015;7(1):25.
   PubMed Web of Science ®Google Scholar
• Lyall MJ, Cartier J, Richards JA, et al. Methyl donor deficient diets cause distinct alterations in lipid metabolism but are poorly representative of human NAFLD. Wellcome Open Res. 2017;2:67.
   PubMedGoogle Scholar
• Mato JM, Martinez-Chantar ML, Lu SC. S-adenosylmethionine metabolism and liver disease. Ann Hepatol. 2013 Mar-Apr;12(2):183–189.
   PubMed Web of Science ®Google Scholar
• Nestor CE, Ottaviano R, Reddington J, et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res. 2012 Mar 1;22(3):467–477.
   PubMed Web of Science ®Google Scholar
• Thomson JP, Hunter JM, Lempiainen H, et al. Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug exposed liver. Nucleic Acids Res. 2013 Jun;41(11):5639–5654.
   PubMed Web of Science ®Google Scholar
• Szulwach KE, Li X, Li Y, et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci. 2011;14(12):1607–1616.
   PubMed Web of Science ®Google Scholar
• Ivanov M, Kals M, Kacevska M, et al. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol. 2013;14(8):R83.
   PubMed Web of Science ®Google Scholar
• Thomson JP, Hunter JM, Lempiäinen H, et al. Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug exposed liver. Nucleic Acids Res. 2013;17:2013.
   Google Scholar
• Ito S, D’Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466(7310):1129–1133.
   PubMed Web of Science ®Google Scholar
• Bachman M, Uribe-Lewis S, Yang X, et al. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat Chem. 2014 Dec;6(12):1049–1055.
   PubMed Web of Science ®Google Scholar
• Nestor C, Ruzov A, Meehan RR, et al. Enzymatic approaches and bisulfite sequencing cannot distinguish between 5-methylcytosine and 5-hydroxymethylcytosine in DNA. Biotechniques. 2010;48:317–319.
   PubMed Web of Science ®Google Scholar
• Huang Y, Pastor WA, Shen Y, et al. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One. 2010 Jan 26;5(1):e8888.
   PubMed Web of Science ®Google Scholar
• Meehan RR, Thomson JP, Lentini A, et al. DNA methylation as a genomic marker of exposure to chemical and environmental agents. Curr Opin Chem Biol. 2018;45:48–56.
   PubMed Web of Science ®Google Scholar
• Thomson JP, Ottaviano R, Unterberger E, et al. Loss of Tet1 associated 5-hydroxymethylcytosine is concomitant with aberrant promoter hypermethylation in liver cancer. Cancer Res. 2016;76(10):3097–3108.
   PubMed Web of Science ®Google Scholar
• Sajadian SO, Ehnert S, Vakilian H, et al. Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma. Clin Epigenetics. 2015;7:98.
   PubMed Web of Science ®Google Scholar
• Winzell MS, Ahrén B. The high-fat diet–fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes. 2004 Dec 1;53(suppl 3):S215–S219.
   PubMed Web of Science ®Google Scholar
• Lake AD, Novak P, Fisher CD, et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011 Oct;39(10):1954–1960.
   PubMed Web of Science ®Google Scholar
• Thomson JP, Fawkes A, Ottaviano R, et al. DNA immunoprecipitation semiconductor sequencing (DIP-SC-seq) as a rapid method to generate genome wide epigenetic signatures [Article]. Sci Rep. 2015;5:9778.
   PubMed Web of Science ®Google Scholar
• Nilsson E, Matte A, Perfilyev A, et al. Epigenetic alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels. J Clin Endocrinol Metab. 2015 Nov;100(11):E1491–E1501.
   PubMed Web of Science ®Google Scholar
• Kulinski A, Vance DE, Vance JE. A choline-deficient diet in mice inhibits neither the CDP-choline pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion. J Biol Chem. 2004 Jun 4;279(23):23916–23924.
   PubMed Web of Science ®Google Scholar
• Salbe AD, Weyer C, Harper I, et al. Assessing risk factors for obesity between childhood and adolescence: II. Energy metabolism and physical activity. Pediatrics. 2002;110(2 Pt 1):307–314.
   PubMed Web of Science ®Google Scholar
• Leung C, Yeoh SW, Patrick D, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol. 2015 Jan 28;21(4):1189–1196.
   PubMed Web of Science ®Google Scholar
• Kammel A, Saussenthaler S, Jahnert M, et al. Early hypermethylation of hepatic Igfbp2 results in its reduced expression preceding fatty liver in mice. Hum Mol Genet. 2016 Jun 15;25(12):2588–2599.
   PubMed Web of Science ®Google Scholar
• Hedbacker K, Birsoy K, Wysocki RW, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab. 2010 Jan;11(1):11–22.
   PubMed Web of Science ®Google Scholar
• Lyall MJ, Cartier J, Thomson JP, et al. Modelling non-alcoholic fatty liver disease in human hepatocyte-like cells. Philos Trans R Soc Lond B Biol Sci. 2018 Jul 5;373(1750). pii: 20170362. doi:10.1098/rstb.2017.0362.
   PubMed Web of Science ®Google Scholar
• Paish HL, Reed LH, Brown H, et al. A novel bioreactor technology for modelling fibrosis in human and rodent precision-cut liver slices. Hepatology. 2019 Apr 4.
   Web of Science ®Google Scholar
• Hardy T, Zeybel M, Day CP, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut. 2017 Jul;66(7):1321–1328.
   PubMed Web of Science ®Google Scholar
• Song CX, Yin S, Ma L, et al. 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Res. 2017 Oct;27(10):1231–1242.
   PubMed Web of Science ®Google Scholar
• Moran-Salvador E, Mann J. Epigenetics and liver fibrosis. Cell Mol Gastroenterol Hepatol. 2017 Jul;4(1):125–134.
   PubMed Web of Science ®Google Scholar
• Aad G, Abbott B, Abdallah J, et al. Search for dilepton resonances in pp collisions at radicals=7 TeV with the ATLAS detector. Phys Rev Lett. 2011 Dec 30;107(27):272002.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313–1321.
   PubMed Web of Science ®Google Scholar
• Hoy AM, McDonald N, Lennen RJ, et al. Non-invasive assessment of liver disease in rats using multiparametric magnetic resonance imaging: a feasibility study. Biol Open. 2018 Jul 2;7(7).
   PubMed Web of Science ®Google Scholar